TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer
Clinical trial NCT01455389 · TERMINATED
Trial details
- NCT number
- NCT01455389
- Sponsor
- Genprex, Inc.
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-02-01
- Primary completion
- 2016-10-27
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.